ClinVar Miner

Submissions for variant NM_000057.4(BLM):c.3228T>G (p.Asp1076Glu)

dbSNP: rs2151190260
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001371339 SCV001567898 uncertain significance Bloom syndrome 2021-08-31 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid with glutamic acid at codon 1076 of the BLM protein (p.Asp1076Glu). The aspartic acid residue is moderately conserved and there is a small physicochemical difference between aspartic acid and glutamic acid. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with BLM-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Sema4, Sema4 RCV002259109 SCV002530116 uncertain significance Hereditary cancer-predisposing syndrome 2021-05-06 criteria provided, single submitter curation
Ambry Genetics RCV002259109 SCV003863725 uncertain significance Hereditary cancer-predisposing syndrome 2022-11-10 criteria provided, single submitter clinical testing The p.D1076E variant (also known as c.3228T>G), located in coding exon 16 of the BLM gene, results from a T to G substitution at nucleotide position 3228. The aspartic acid at codon 1076 is replaced by glutamic acid, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.